Drug Profile
Research programme: cancer vaccines - AEterna Zentaris
Alternative Names: AEZS-120; Bacterial cancer vaccines - AEterna Zentaris; Oral prostate cancer vaccine (AEZS-120) - AEterna ZentarisLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator AEterna Zentaris Inc
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer; Malignant melanoma; Prostate cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Germany (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Malignant-melanoma in Germany (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Prostate-cancer in Germany (PO)